MAXIMUS, INC. quarterly report, Q3 FY2017

MAXIMUS, Inc. Form 10-Q Summary

Business Context and Reporting Period

MAXIMUS provides business-process, technology, health, federal, and human-services programs to government agencies worldwide. This unaudited Form 10-Q covers the three and nine months ended June 30, 2017, within fiscal 2017, compared with the corresponding 2016 periods.

Key Financial Metrics

MetricThree Months 2017Three Months 2016Nine Months 2017Nine Months 2016
Revenue$600.4 million$617.1 million$1,830.1 million$1,780.3 million
Gross profit$152.2 million$151.4 million$449.3 million$409.3 million
Gross margin25.3%24.5%24.6%23.0%
Operating income$81.8 million$84.6 million$235.9 million$205.3 million
Operating margin13.6%13.7%12.9%11.5%
Net income attributable to MAXIMUS$56.9 million$52.2 million$156.1 million$127.6 million
Diluted EPS$0.86$0.79$2.36$1.93
  • Cash flow from operations was $252.1 million for the nine months, versus $108.1 million in the prior-year period. Free cash flow was $233.0 million versus $74.0 million.
  • Cash and cash equivalents were $104.4 million at June 30, 2017, including $101.1 million held by foreign subsidiaries.
  • Total debt was approximately $15.7 million, consisting primarily of $15.0 million drawn under the credit facility. The company subsequently repaid the remaining credit-facility balance in July 2017. The facility provides capacity of up to $400 million and expires in March 2020.
  • The company was in compliance with debt covenants; its total leverage ratio was below 1.0-to-1.0 at June 30, 2017.
  • Accounts receivable, billed and unbilled, totaled $420.7 million. Days sales outstanding improved to 64 days from 70 days at the beginning of fiscal 2017.
  • The company repurchased approximately 0.6 million shares for $28.9 million during the nine months. Remaining authorization was $109.3 million at June 30, 2017. Dividends paid were $8.8 million.

Material Changes Versus the Prior Comparable Period

  • Nine-month revenue increased 2.8%, despite a $37.6 million adverse currency effect. Third-quarter revenue declined 2.7%, primarily because of the U.S. Federal Services subcontract wind-down and foreign-exchange effects.
  • Health Services revenue increased 7.2% for the nine months, including 9.6% organic growth. Operating margin improved to 15.4% from 14.0%, supported by contract expansion, improved performance on the U.K. HAAS contract, and lower penalties.
  • U.S. Federal Services revenue decreased 6.0% for the nine months and 12% in the quarter as a large U.S. Veterans Administration subcontract ended in April 2017. Margin improved year over year for the nine-month period because of automation and lower-cost execution.
  • Human Services revenue increased 2.1% for the nine months, but gross margin declined to 24.2% from 25.6%, principally because the U.K. Work Programme was winding down. Operating margin nevertheless improved to 9.8% from 8.7%.
  • Gross margin expanded materially for the nine-month period, while third-quarter operating margin was broadly stable. Nine-month results included $2.2 million of U.K. restructuring costs, primarily severance.
  • The prior-year period included a $6.5 million gain on the sale of the K-12 Education business and $2.8 million of legal costs. The current period included an additional $0.7 million gain related to release of a sale contingency.
  • The effective tax rate was 33.3% for the nine months versus 37.2% in 2016. Third-quarter results benefited from approximately $3.7 million of prior-period U.S. and Canadian research-and-development tax credits and a $2.8 million discrete benefit related to restricted-stock-unit vesting.

Guidance, Outlook, Risks, and Unusual Items

  • Management stated that short-term growth is more likely to be in the single digits as governments reassess priorities, legislation, and programs. It remains positive on longer-term opportunities from aging populations, rising health-care demand, and government reform initiatives.
  • Management expects a full-year tax rate of approximately 33% to 34%. Certain third-quarter tax and interest benefits were described as nonrecurring.
  • The July 2017 acquisition of Revitalised Limited added digital health, fitness, and wellbeing capabilities in the United Kingdom. Consideration was $2.8 million in cash plus up to $1.6 million of contingent consideration; purchase accounting was not complete at the filing date.
  • Key risks include contract termination or penalties, inaccurate pricing or failure to meet performance requirements, government budget and legislative changes, information-security failures, personnel retention, contract-payment timing, audits and compliance matters, litigation, foreign-currency exposure, and acquisition integration.
  • At June 30, 2017, foreign-currency net assets were $191.6 million; a 10% currency movement could affect comprehensive income by approximately $19.2 million.
  • The company reported no material changes to the risk factors in its fiscal 2016 Form 10-K, no material adverse legal matter known to management, and effective disclosure controls.
  • The company will adopt the new revenue-recognition standard in fiscal 2019 and anticipates using the retrospective transition method. Lease accounting changes are expected to apply in fiscal 2020.
  • The board declared a quarterly dividend of $0.045 per share on July 7, 2017, payable August 31, 2017.

Important Facts for Investors to Verify

  • Whether the Federal Services revenue decline has been fully absorbed and whether replacement contract wins offset the subcontract wind-down.
  • The sustainability of Health Services margin gains, including HAAS performance improvements and the pending change order involving approximately $4 million of unrecognized revenue.
  • The duration and financial impact of the U.K. Work Programme wind-down and related restructuring savings.
  • The recurring tax rate after the nonrecurring research-and-development credits and restricted-stock-unit tax benefit.
  • The availability and location of cash, particularly the $101.1 million held outside the United States, and any implications of future repatriation.
  • The final purchase accounting and contingent consideration for Revitalised and the performance of recently acquired businesses.
  • Future exposure to government audits, contract compliance claims, litigation, and foreign-exchange movements.